Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$571K Sell
124,158
-31,132
-20% -$207K ﹤0.01% 6145
2026
Q1
$1.07M Buy
155,290
+49,244
+46% +$478K ﹤0.01% 5500
2025
Q4
$1.07M Buy
106,046
+81,928
+340% +$1.16M ﹤0.01% 5503
2025
Q3
$309K Buy
24,118
+10,357
+75% +$135K ﹤0.01% 6421
2025
Q2
$139K Buy
+13,761
New +$158K ﹤0.01% 6974
2025
Q1
– Sell
-12,620
Closed -$227K – 10568
2024
Q4
$227K Buy
12,620
+12,421
+6,242% +$241K ﹤0.01% 6376
2024
Q3
$3.65K Buy
199
+182
+1,071% +$3.02K ﹤0.01% 8239
2024
Q2
$304 Sell
17
-438
-96% -$9.79K ﹤0.01% 8989
2024
Q1
$10.2K Buy
455
+396
+671% +$7.99K ﹤0.01% 7242
2023
Q4
$1.15K Buy
+59
New +$1.1K ﹤0.01% 8393
2023
Q2
– Sell
-690
Closed -$24.8K – 9418
2023
Q1
$24.8K Buy
690
+680
+6,800% +$29.8K ﹤0.01% 6919
2022
Q4
$410 Hold
10
– – ﹤0.01% 10198
2022
Q3
$0 Hold
10
– – ﹤0.01% 10737
2022
Q2
$1K Buy
+10
New +$1.24K ﹤0.01% 9924

Other funds holding NVX

UBS Group's NVX Position: Q2 2026 in Review

UBS Group reduced its NOVONIX (NVX) stake by 20% in Q2 2026, selling an estimated $207K and leaving 124,158 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #6145.

UBS Group first reported a position in NVX in Q2 2022 and has held it in 14 quarters since. The position peaked at $1.07M in Q1 2026. 25 funds tracked by Wall St. Rank hold NVX as of Q2 2026.

  • UBS Group held 124,158 shares of NOVONIX worth $571K as of Q2 2026.
  • UBS Group sold 31,132 NOVONIX shares in Q2 2026, an estimated $207K.
  • NOVONIX made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6145 holding.
  • UBS Group first reported a position in NOVONIX in Q2 2022 and has held it in 14 quarters since.
  • UBS Group's NOVONIX position peaked at $1.07M in Q1 2026.
  • 25 funds tracked by Wall St. Rank held NOVONIX as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.